ALVR AlloVir | $0.68
| 12/22/2023 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of AlloVir (NASDAQ:ALVR) on 12/22/2023 |
WVE Wave Life Sciences | $5.05 -0.2% | 12/19/2023 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $5.00 -> $12.00 | Low | View details for SVB Leerink rating of Wave Life Sciences (NASDAQ:WVE) on 12/19/2023 |
RPHM Reneo Pharmaceuticals | $1.60
| 12/15/2023 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of Reneo Pharmaceuticals (NASDAQ:RPHM) on 12/15/2023 |
INCY Incyte | $62.79 +0.1% | 12/13/2023 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $78.00 | Low | View details for SVB Leerink rating of Incyte (NASDAQ:INCY) on 12/13/2023 |
NBTX Nanobiotix | $7.28 -3.6% | 12/8/2023 | Initiated by | SVB Leerink | - | Outperform | $11.00 | Low | View details for SVB Leerink rating of Nanobiotix (NASDAQ:NBTX) on 12/8/2023 |
TNYA Tenaya Therapeutics | $3.24 -4.4% | 11/30/2023 | Initiated by | SVB Leerink | - | Outperform | $7.00 | Low | View details for SVB Leerink rating of Tenaya Therapeutics (NASDAQ:TNYA) on 11/30/2023 |
|
LXEO Lexeo Therapeutics | $13.42 -7.8% | 11/28/2023 | Initiated by | SVB Leerink | - | Outperform | $19.00 | Low | View details for SVB Leerink rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/28/2023 |
ABVX ABIVAX Société Anonyme | $10.70 -0.9% | 11/14/2023 | Initiated by | SVB Leerink | - | Outperform | $20.00 | Low | View details for SVB Leerink rating of ABIVAX Société Anonyme (NASDAQ:ABVX) on 11/14/2023 |
MRTX Mirati Therapeutics | $58.75 -0.3% | 11/7/2023 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | $78.00 -> $58.00 | Low | View details for SVB Leerink rating of Mirati Therapeutics (NASDAQ:MRTX) on 11/7/2023 |
ZNTL Zentalis Pharmaceuticals | $15.15 -2.8% | 11/7/2023 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $15.00 | Low | View details for SVB Leerink rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on 11/7/2023 |
TSVT 2seventy bio | $4.27 -6.8% | 10/30/2023 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $6.00 | Low | View details for SVB Leerink rating of 2seventy bio (NASDAQ:TSVT) on 10/30/2023 |
BEAM Beam Therapeutics | $27.22 -7.5% | 10/20/2023 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $75.00 -> $20.00 | Low | View details for SVB Leerink rating of Beam Therapeutics (NASDAQ:BEAM) on 10/20/2023 |
FDMT 4D Molecular Therapeutics | $20.26 -3.6% | 10/18/2023 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $24.00 | Low | View details for SVB Leerink rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 10/18/2023 |
AXGN AxoGen | $6.83 -0.7% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $9.00 | Low | View details for SVB Leerink rating of AxoGen (NASDAQ:AXGN) on 10/16/2023 |
AXNX Axonics | $62.23 -2.4% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $70.00 | Low | View details for SVB Leerink rating of Axonics (NASDAQ:AXNX) on 10/16/2023 |
PRCT PROCEPT BioRobotics | $41.91 -2.4% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $37.00 | Low | View details for SVB Leerink rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 10/16/2023 |
DXCM DexCom | $124.09 -0.1% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $110.00 | Low | View details for SVB Leerink rating of DexCom (NASDAQ:DXCM) on 10/16/2023 |
EW Edwards Lifesciences | $76.25 -0.6% | 10/16/2023 | Initiated by | SVB Leerink | - | Market Perform | $75.00 | Low | View details for SVB Leerink rating of Edwards Lifesciences (NYSE:EW) on 10/16/2023 |
SWAV Shockwave Medical | $190.56 -0.4% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $263.00 | Low | View details for SVB Leerink rating of Shockwave Medical (NASDAQ:SWAV) on 10/16/2023 |
INSP Inspire Medical Systems | $203.43 -0.2% | 10/16/2023 | Initiated by | SVB Leerink | - | Market Perform | $159.00 | Low | View details for SVB Leerink rating of Inspire Medical Systems (NYSE:INSP) on 10/16/2023 |
TNDM Tandem Diabetes Care | $29.58 -3.8% | 10/16/2023 | Initiated by | SVB Leerink | - | Market Perform | $21.00 | Low | View details for SVB Leerink rating of Tandem Diabetes Care (NASDAQ:TNDM) on 10/16/2023 |
ISRG Intuitive Surgical | $337.36 -0.3% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $342.00 | Low | View details for SVB Leerink rating of Intuitive Surgical (NASDAQ:ISRG) on 10/16/2023 |
VCEL Vericel | $35.61 -1.1% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $42.00 | Low | View details for SVB Leerink rating of Vericel (NASDAQ:VCEL) on 10/16/2023 |
PODD Insulet | $216.98 -1.1% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $184.00 | Low | View details for SVB Leerink rating of Insulet (NASDAQ:PODD) on 10/16/2023 |
AMGN Amgen | $288.02 -0.2% | 10/11/2023 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $267.00 -> $318.00 | Low | View details for SVB Leerink rating of Amgen (NASDAQ:AMGN) on 10/11/2023 |
NBIX Neurocrine Biosciences | $131.76 -0.3% | 10/6/2023 | Target Raised by | SVB Leerink | Analyst M. Goodman | | $125.00 -> $135.00 | Low | View details for SVB Leerink rating of Neurocrine Biosciences (NASDAQ:NBIX) on 10/6/2023 |
PNT POINT Biopharma Global | $12.50
| 10/6/2023 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of POINT Biopharma Global (NASDAQ:PNT) on 10/6/2023 |
GPCR Structure Therapeutics | $40.76 +10.3% | 9/29/2023 | Target Raised by | SVB Leerink | - | | $46.00 -> $97.00 | Low | View details for SVB Leerink rating of Structure Therapeutics (NASDAQ:GPCR) on 9/29/2023 |
SPRY ARS Pharmaceuticals | $5.48 -2.7% | 9/21/2023 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/21/2023 |
PTCT PTC Therapeutics | $27.56 -3.6% | 9/18/2023 | Target Lowered by | SVB Leerink | Analyst J. Schwartz | | $44.00 -> $30.00 | Low | View details for SVB Leerink rating of PTC Therapeutics (NASDAQ:PTCT) on 9/18/2023 |
SPRB Spruce Biosciences | $2.93 +2.8% | 9/8/2023 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $3.00 -> $9.00 | Low | View details for SVB Leerink rating of Spruce Biosciences (NASDAQ:SPRB) on 9/8/2023 |
ABCM Abcam | $23.99
| 8/29/2023 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of Abcam (NASDAQ:ABCM) on 8/29/2023 |
GLTO Galecto | $0.72 -7.7% | 8/15/2023 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | $13.00 -> $2.00 | Low | View details for SVB Leerink rating of Galecto (NASDAQ:GLTO) on 8/15/2023 |
DSGN Design Therapeutics | $2.65 -4.0% | 8/15/2023 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | $6.00 | Low | View details for SVB Leerink rating of Design Therapeutics (NASDAQ:DSGN) on 8/15/2023 |
CYTK Cytokinetics | $83.49 +0.3% | 8/15/2023 | Initiated by | SVB Leerink | - | Outperform | $58.00 | Low | View details for SVB Leerink rating of Cytokinetics (NASDAQ:CYTK) on 8/15/2023 |
EXEL Exelixis | $23.99 -0.6% | 8/8/2023 | Initiated by | SVB Leerink | - | Market Perform | $18.00 | Low | View details for SVB Leerink rating of Exelixis (NASDAQ:EXEL) on 8/8/2023 |
IDYA IDEAYA Biosciences | $35.58 -0.7% | 8/8/2023 | Initiated by | SVB Leerink | - | Outperform | $33.00 | Low | View details for SVB Leerink rating of IDEAYA Biosciences (NASDAQ:IDYA) on 8/8/2023 |
NUVL Nuvalent | $73.59 -2.0% | 8/8/2023 | Initiated by | SVB Leerink | - | Market Perform | $42.00 | Low | View details for SVB Leerink rating of Nuvalent (NASDAQ:NUVL) on 8/8/2023 |
NVCR NovoCure | $14.93 -5.4% | 8/4/2023 | Initiated by | SVB Leerink | - | Outperform | $51.00 | Low | View details for SVB Leerink rating of NovoCure (NASDAQ:NVCR) on 8/4/2023 |
BLTE Belite Bio | $45.75 -0.3% | 7/26/2023 | Reiterated by | SVB Leerink | Analyst M. Goodman | Outperform | $25.00 | Low | View details for SVB Leerink rating of Belite Bio (NASDAQ:BLTE) on 7/26/2023 |
|
NBIX Neurocrine Biosciences | $131.76 -0.3% | 7/24/2023 | Upgraded by | SVB Leerink | Analyst M. Goodman | Market Perform -> Outperform | | Low | View details for SVB Leerink rating of Neurocrine Biosciences (NASDAQ:NBIX) on 7/24/2023 |
CYRX Cryoport | $15.49 -3.0% | 7/13/2023 | Downgraded by | SVB Leerink | Analyst P. Souda | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of Cryoport (NASDAQ:CYRX) on 7/13/2023 |
BMY Bristol-Myers Squibb | $51.31 +0.2% | 7/10/2023 | Reiterated by | SVB Leerink | Analyst D. Risinger | Market Perform | | Low | View details for SVB Leerink rating of Bristol-Myers Squibb (NYSE:BMY) on 7/10/2023 |
EHAB Enhabit | $10.35 -2.5% | 6/20/2023 | Reiterated by | SVB Leerink | Analyst W. Mayo | Underperform | | Low | View details for SVB Leerink rating of Enhabit (NYSE:EHAB) on 6/20/2023 |
OCS Oculis | $11.23 +1.2% | 6/12/2023 | Reiterated by | SVB Leerink | Analyst M. Goodman | Outperform | | Low | View details for SVB Leerink rating of Oculis (NASDAQ:OCS) on 6/12/2023 |
BPMC Blueprint Medicines | $92.24 +1.0% | 6/5/2023 | Downgraded by | SVB Leerink | Analyst A. Berens | Market Perform -> Underperform | | Low | View details for SVB Leerink rating of Blueprint Medicines (NASDAQ:BPMC) on 6/5/2023 |
ELEV Elevation Oncology | $0.54 -1.8% | 5/30/2023 | Upgraded by | SVB Leerink | Analyst A. Berens | Market Perform -> Outperform | | Low | View details for SVB Leerink rating of Elevation Oncology (NASDAQ:ELEV) on 5/30/2023 |
RAIN Rain Oncology | $1.20
| 5/22/2023 | Downgraded by | SVB Leerink | Analyst F. Khurshid | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of Rain Oncology (NASDAQ:RAIN) on 5/22/2023 |
BOLT Bolt Biotherapeutics | $1.12 +4.7% | 5/12/2023 | Upgraded by | SVB Leerink | Analyst D. Graybosch | Market Perform -> Outperform | | Low | View details for SVB Leerink rating of Bolt Biotherapeutics (NASDAQ:BOLT) on 5/12/2023 |
ARWR Arrowhead Pharmaceuticals | $30.60 -1.3% | 5/12/2023 | Downgraded by | SVB Leerink | Analyst M. Foroohar | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 5/12/2023 |
DHR Danaher | $231.34 -0.8% | 5/1/2023 | Reiterated by | SVB Leerink | Analyst P. Souda | Outperform | | Low | View details for SVB Leerink rating of Danaher (NYSE:DHR) on 5/1/2023 |
PRTA Prothena | $36.34 -5.5% | 4/24/2023 | Reiterated by | SVB Leerink | Analyst R. Li | Outperform | | Low | View details for SVB Leerink rating of Prothena (NASDAQ:PRTA) on 4/24/2023 |
GNFT Genfit | $3.85
| 4/14/2023 | Reiterated by | SVB Leerink | Analyst T. Smith | Outperform | | Low | View details for SVB Leerink rating of Genfit (NASDAQ:GNFT) on 4/14/2023 |
CNTB Connect Biopharma | $1.18 +7.3% | 4/12/2023 | Reiterated by | SVB Leerink | Analyst T. Smith | Outperform | | Low | View details for SVB Leerink rating of Connect Biopharma (NASDAQ:CNTB) on 4/12/2023 |
ARWR Arrowhead Pharmaceuticals | $30.60 -1.3% | 4/12/2023 | Upgraded by | SVB Leerink | Analyst M. Foroohar | Market Perform -> Outperform | | Low | View details for SVB Leerink rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 4/12/2023 |
CORT Corcept Therapeutics | $32.48 -1.2% | 4/11/2023 | Reiterated by | SVB Leerink | Analyst R. Ruiz | Market Perform | $25.00 | Low | View details for SVB Leerink rating of Corcept Therapeutics (NASDAQ:CORT) on 4/11/2023 |
ACLX Arcellx | $55.50 -2.4% | 3/30/2023 | Target Raised by | SVB Leerink | - | Outperform | $35.00 -> $39.00 | Low | View details for SVB Leerink rating of Arcellx (NASDAQ:ACLX) on 3/30/2023 |
ABT Abbott Laboratories | $110.07 -0.3% | 3/31/2023 | Target Raised by | SVB Leerink | - | Market Perform | $90.00 -> $102.00 | Low | View details for SVB Leerink rating of Abbott Laboratories (NYSE:ABT) on 3/31/2023 |
REGN Regeneron Pharmaceuticals | $878.29 -0.4% | 3/27/2023 | Upgraded by | SVB Leerink | Analyst D. Risinger | Market Perform -> Outperform | | Low | View details for SVB Leerink rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 3/27/2023 |
RAIN Rain Oncology | $1.20
| 3/21/2023 | Reiterated by | SVB Leerink | Analyst F. Khurshid | Outperform | $11.00 | Low | View details for SVB Leerink rating of Rain Oncology (NASDAQ:RAIN) on 3/21/2023 |
PTCT PTC Therapeutics | $27.56 -3.6% | 3/17/2023 | Reiterated by | SVB Leerink | Analyst J. Schwartz | Market Perform | $48.00 | Low | View details for SVB Leerink rating of PTC Therapeutics (NASDAQ:PTCT) on 3/17/2023 |
CNTA Centessa Pharmaceuticals | $7.96 -0.9% | 3/17/2023 | Reiterated by | SVB Leerink | Analyst D. Risinger | Outperform | $6.00 | Low | View details for SVB Leerink rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 3/17/2023 |
HALO Halozyme Therapeutics | $36.96 -0.5% | 3/16/2023 | Downgraded by | SVB Leerink | Analyst D. Risinger | Outperform -> Market Perform | $42.00 | Low | View details for SVB Leerink rating of Halozyme Therapeutics (NASDAQ:HALO) on 3/16/2023 |
MORF Morphic | $28.88 -2.7% | 3/8/2023 | Target Raised by | SVB Leerink | - | Outperform | $45.00 -> $56.00 | Low | View details for SVB Leerink rating of Morphic (NASDAQ:MORF) on 3/8/2023 |
ARGX argenx | $380.43 +0.0% | 3/3/2023 | Target Raised by | SVB Leerink | - | Outperform | $430.00 -> $435.00 | Low | View details for SVB Leerink rating of argenx (NASDAQ:ARGX) on 3/3/2023 |
GPCR Structure Therapeutics | $40.76 +10.3% | 2/28/2023 | Reiterated by | SVB Leerink | Analyst D. Risinger | Outperform | | Low | View details for SVB Leerink rating of Structure Therapeutics (NASDAQ:GPCR) on 2/28/2023 |
CGEN Compugen | $1.98 +11.2% | 2/28/2023 | Reiterated by | SVB Leerink | Analyst D. Graybosch | Outperform | | Low | View details for SVB Leerink rating of Compugen (NASDAQ:CGEN) on 2/28/2023 |
IRON Disc Medicine | $57.76 +1.4% | 2/28/2023 | Reiterated by | SVB Leerink | Analyst T. Smith | Outperform | $36.00 | Low | View details for SVB Leerink rating of Disc Medicine (NASDAQ:IRON) on 2/28/2023 |
XNCR Xencor | $21.23 -0.9% | 2/23/2023 | Reiterated by | SVB Leerink | Analyst J. Chang | Outperform | | Low | View details for SVB Leerink rating of Xencor (NASDAQ:XNCR) on 2/23/2023 |
MRNA Moderna | $99.45 +0.7% | 2/24/2023 | Downgraded by | SVB Leerink | Analyst M. Foroohar | Market Perform -> Underperform | $111.00 -> $93.00 | Low | View details for SVB Leerink rating of Moderna (NASDAQ:MRNA) on 2/24/2023 |
NKTR Nektar Therapeutics | $0.57 +1.8% | 2/24/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $5.00 -> $3.00 | N/A | View details for SVB Leerink rating of Nektar Therapeutics (NASDAQ:NKTR) on 2/24/2023 |
BPMC Blueprint Medicines | $92.24 +1.0% | 2/24/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $45.00 -> $38.00 | Low | View details for SVB Leerink rating of Blueprint Medicines (NASDAQ:BPMC) on 2/24/2023 |
IONS Ionis Pharmaceuticals | $50.59 +0.2% | 2/23/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $34.00 -> $27.00 | Low | View details for SVB Leerink rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 2/23/2023 |
TDOC Teladoc Health | $21.55 -2.5% | 2/23/2023 | Upgraded by | SVB Leerink | Analyst S. Davis | Market Perform -> Outperform | $34.00 | Low | View details for SVB Leerink rating of Teladoc Health (NYSE:TDOC) on 2/23/2023 |
ABBV AbbVie | $154.97 +0.1% | 2/10/2023 | Upgraded by | SVB Leerink | Analyst D. Risinger | Underperform -> Market Perform | $135.00 -> $153.00 | Low | View details for SVB Leerink rating of AbbVie (NYSE:ABBV) on 2/10/2023 |
ENTA Enanta Pharmaceuticals | $9.41 -3.6% | 2/9/2023 | Reiterated by | SVB Leerink | - | Market Perform | $49.00 | Low | View details for SVB Leerink rating of Enanta Pharmaceuticals (NASDAQ:ENTA) on 2/9/2023 |
CBAY CymaBay Therapeutics | $23.62 -1.5% | 2/8/2023 | Target Raised by | SVB Leerink | - | Outperform | $10.00 -> $12.00 | Low | View details for SVB Leerink rating of CymaBay Therapeutics (NASDAQ:CBAY) on 2/8/2023 |
CNTB Connect Biopharma | $1.18 +7.3% | 2/8/2023 | Target Lowered by | SVB Leerink | - | Outperform | $9.00 -> $7.00 | Low | View details for SVB Leerink rating of Connect Biopharma (NASDAQ:CNTB) on 2/8/2023 |
EQ Equillium | $0.72 +5.9% | 2/8/2023 | Target Lowered by | SVB Leerink | - | Outperform | $12.00 -> $7.00 | Low | View details for SVB Leerink rating of Equillium (NASDAQ:EQ) on 2/8/2023 |
CI The Cigna Group | $299.45 +0.0% | 2/8/2023 | Target Raised by | SVB Leerink | - | Market Perform | $309.00 -> $335.00 | Low | View details for SVB Leerink rating of The Cigna Group (NYSE:CI) on 2/8/2023 |
PINC Premier | $22.36 -0.5% | 2/8/2023 | Target Lowered by | SVB Leerink | - | Outperform | $46.00 -> $42.00 | Low | View details for SVB Leerink rating of Premier (NASDAQ:PINC) on 2/8/2023 |
ILMN Illumina | $139.24 -2.0% | 2/8/2023 | Target Raised by | SVB Leerink | Analyst P. Souda | Outperform | $249.00 -> $250.00 | Low | View details for SVB Leerink rating of Illumina (NASDAQ:ILMN) on 2/8/2023 |
VRTX Vertex Pharmaceuticals | $406.89 -0.6% | 2/8/2023 | Target Lowered by | SVB Leerink | - | Outperform | $374.00 -> $365.00 | Low | View details for SVB Leerink rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 2/8/2023 |
INCY Incyte | $62.79 +0.1% | 2/8/2023 | Reiterated by | SVB Leerink | - | Underperform | $63.00 | Low | View details for SVB Leerink rating of Incyte (NASDAQ:INCY) on 2/8/2023 |
DCPH Deciphera Pharmaceuticals | $16.13 -1.8% | 2/7/2023 | Target Raised by | SVB Leerink | - | Outperform | $28.00 -> $30.00 | Low | View details for SVB Leerink rating of Deciphera Pharmaceuticals (NASDAQ:DCPH) on 2/7/2023 |
GMAB Genmab A/S | $31.84 -0.3% | 2/6/2023 | Target Raised by | SVB Leerink | - | Market Perform | $33.00 -> $36.00 | Low | View details for SVB Leerink rating of Genmab A/S (NASDAQ:GMAB) on 2/6/2023 |
FDMT 4D Molecular Therapeutics | $20.26 -3.6% | 2/6/2023 | Target Lowered by | SVB Leerink | Analyst M. Foroohar | Market Perform | $15.00 -> $14.00 | Low | View details for SVB Leerink rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 2/6/2023 |
IMVT Immunovant | $42.13 -0.5% | 2/6/2023 | Target Raised by | SVB Leerink | - | Outperform | $14.00 -> $21.00 | Low | View details for SVB Leerink rating of Immunovant (NASDAQ:IMVT) on 2/6/2023 |
SGEN Seagen | $228.74
| 2/6/2023 | Downgraded by | SVB Leerink | Analyst Andrew Berens | Outperform -> Market Perform | $162.00 -> $141.00 | Low | View details for SVB Leerink rating of Seagen (NASDAQ:SGEN) on 2/6/2023 |
REGN Regeneron Pharmaceuticals | $878.29 -0.4% | 2/6/2023 | Target Raised by | SVB Leerink | Analyst D. Risinger | Market Perform | $770.00 -> $834.00 | Low | View details for SVB Leerink rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 2/6/2023 |
|
GILD Gilead Sciences | $81.01 -0.2% | 2/3/2023 | Target Raised by | SVB Leerink | Analyst D. Risinger | Market Perform | $81.00 -> $91.00 | Low | View details for SVB Leerink rating of Gilead Sciences (NASDAQ:GILD) on 2/3/2023 |
TECH Bio-Techne | $77.16 -1.4% | 2/3/2023 | Target Lowered by | SVB Leerink | - | Outperform | $125.00 -> $110.00 | Low | View details for SVB Leerink rating of Bio-Techne (NASDAQ:TECH) on 2/3/2023 |
BMRN BioMarin Pharmaceutical | $96.42 -0.7% | 2/3/2023 | Target Raised by | SVB Leerink | - | Outperform | $122.00 -> $130.00 | Low | View details for SVB Leerink rating of BioMarin Pharmaceutical (NASDAQ:BMRN) on 2/3/2023 |
IONS Ionis Pharmaceuticals | $50.59 +0.2% | 2/3/2023 | Target Raised by | SVB Leerink | - | Market Perform | $33.00 -> $34.00 | Low | View details for SVB Leerink rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 2/3/2023 |
MRK Merck & Co., Inc. | $109.02 +0.2% | 2/3/2023 | Target Raised by | SVB Leerink | - | Outperform | $120.00 -> $122.00 | Low | View details for SVB Leerink rating of Merck & Co., Inc. (NYSE:MRK) on 2/3/2023 |
KALV KalVista Pharmaceuticals | $12.25 +1.4% | 2/3/2023 | Target Lowered by | SVB Leerink | - | Outperform | $30.00 -> $20.00 | Low | View details for SVB Leerink rating of KalVista Pharmaceuticals (NASDAQ:KALV) on 2/3/2023 |
TMO Thermo Fisher Scientific | $530.79 -0.4% | 2/2/2023 | Target Raised by | SVB Leerink | - | Outperform | $620.00 -> $630.00 | Low | View details for SVB Leerink rating of Thermo Fisher Scientific (NYSE:TMO) on 2/2/2023 |
HOLX Hologic | $71.45 +0.3% | 2/2/2023 | Target Raised by | SVB Leerink | - | Outperform | $90.00 -> $93.00 | Low | View details for SVB Leerink rating of Hologic (NASDAQ:HOLX) on 2/2/2023 |
AMGN Amgen | $288.02 -0.2% | 2/2/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $282.00 -> $267.00 | Low | View details for SVB Leerink rating of Amgen (NASDAQ:AMGN) on 2/2/2023 |
PFE Pfizer | $28.79
| 2/1/2023 | Target Lowered by | SVB Leerink | Analyst David Risinger | Market Perform | $49.00 -> $48.00 | Low | View details for SVB Leerink rating of Pfizer (NYSE:PFE) on 2/1/2023 |
OPRX OptimizeRx | $14.31 -1.2% | 1/27/2023 | Reiterated by | SVB Leerink | Analyst S. Davis | Outperform | | Low | View details for SVB Leerink rating of OptimizeRx (NASDAQ:OPRX) on 1/27/2023 |
OMCL Omnicell | $37.63 -3.2% | 1/27/2023 | Reiterated by | SVB Leerink | Analyst S. Davis | Market Perform | | Low | View details for SVB Leerink rating of Omnicell (NASDAQ:OMCL) on 1/27/2023 |
IQV IQVIA | $231.38 -0.6% | 1/27/2023 | Reiterated by | SVB Leerink | Analyst S. Davis | Outperform | | Low | View details for SVB Leerink rating of IQVIA (NYSE:IQV) on 1/27/2023 |
CPSI Computer Programs and Systems | $11.20 -1.5% | 1/27/2023 | Reiterated by | SVB Leerink | Analyst S. Davis | Outperform | | Low | View details for SVB Leerink rating of Computer Programs and Systems (NASDAQ:CPSI) on 1/27/2023 |
DNLI Denali Therapeutics | $21.46 -2.2% | 1/30/2023 | Reiterated by | SVB Leerink | Analyst M. Goodman | Outperform | $50.00 | Low | View details for SVB Leerink rating of Denali Therapeutics (NASDAQ:DNLI) on 1/30/2023 |
AVIR Atea Pharmaceuticals | $3.05 -1.6% | 1/27/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $8.00 -> $6.00 | Low | View details for SVB Leerink rating of Atea Pharmaceuticals (NASDAQ:AVIR) on 1/27/2023 |
ENTA Enanta Pharmaceuticals | $9.41 -3.6% | 1/27/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $50.00 -> $49.00 | Low | View details for SVB Leerink rating of Enanta Pharmaceuticals (NASDAQ:ENTA) on 1/27/2023 |
SCPH scPharmaceuticals | $6.27 -1.9% | 1/27/2023 | Target Raised by | SVB Leerink | Analyst R. Ruiz | Outperform | $12.00 -> $13.00 | Low | View details for SVB Leerink rating of scPharmaceuticals (NASDAQ:SCPH) on 1/27/2023 |
VIR Vir Biotechnology | $10.06 -2.2% | 1/27/2023 | Target Lowered by | SVB Leerink | Analyst R. Ruiz | Outperform | $45.00 -> $43.00 | Low | View details for SVB Leerink rating of Vir Biotechnology (NASDAQ:VIR) on 1/27/2023 |
XERS Xeris Biopharma | $2.35 -0.4% | 1/27/2023 | Target Lowered by | SVB Leerink | - | Outperform | $6.00 -> $5.00 | Low | View details for SVB Leerink rating of Xeris Biopharma (NASDAQ:XERS) on 1/27/2023 |
ELV Elevance Health | $471.56 +0.6% | 1/26/2023 | Reiterated by | SVB Leerink | Analyst W. Mayo | Outperform | $580.00 | Low | View details for SVB Leerink rating of Elevance Health (NYSE:ELV) on 1/26/2023 |
PLRX Pliant Therapeutics | $18.11 -5.2% | 1/24/2023 | Target Raised by | SVB Leerink | - | Outperform | $33.00 -> $45.00 | Low | View details for SVB Leerink rating of Pliant Therapeutics (NASDAQ:PLRX) on 1/24/2023 |
BHVN Biohaven | $42.80 -1.1% | 1/24/2023 | Reiterated by | SVB Leerink | Analyst M. Goodman | Outperform | $24.00 | Low | View details for SVB Leerink rating of Biohaven (NYSE:BHVN) on 1/24/2023 |
MRK Merck & Co., Inc. | $109.02 +0.2% | 1/23/2023 | Target Raised by | SVB Leerink | - | Outperform | $112.00 -> $120.00 | Low | View details for SVB Leerink rating of Merck & Co., Inc. (NYSE:MRK) on 1/23/2023 |
MRNS Marinus Pharmaceuticals | $10.87 -1.1% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $27.00 -> $23.00 | Low | View details for SVB Leerink rating of Marinus Pharmaceuticals (NASDAQ:MRNS) on 1/23/2023 |
RLMD Relmada Therapeutics | $4.14 +9.2% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $42.00 -> $10.00 | Low | View details for SVB Leerink rating of Relmada Therapeutics (NASDAQ:RLMD) on 1/23/2023 |
ALNY Alnylam Pharmaceuticals | $191.41 -2.2% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $144.00 -> $143.00 | Low | View details for SVB Leerink rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 1/23/2023 |
ALVR AlloVir | $0.68
| 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $25.00 -> $19.00 | Low | View details for SVB Leerink rating of AlloVir (NASDAQ:ALVR) on 1/23/2023 |
BBIO BridgeBio Pharma | $40.37 -3.4% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $23.00 -> $19.00 | Low | View details for SVB Leerink rating of BridgeBio Pharma (NASDAQ:BBIO) on 1/23/2023 |
BEAM Beam Therapeutics | $27.22 -7.5% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $81.00 -> $77.00 | Low | View details for SVB Leerink rating of Beam Therapeutics (NASDAQ:BEAM) on 1/23/2023 |
BLUE bluebird bio | $1.38 -2.1% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $9.00 -> $8.00 | Low | View details for SVB Leerink rating of bluebird bio (NASDAQ:BLUE) on 1/23/2023 |
EDIT Editas Medicine | $10.13 -2.1% | 1/23/2023 | Target Raised by | SVB Leerink | Analyst R. Bienkowski | Market Perform | $6.00 -> $7.00 | Low | View details for SVB Leerink rating of Editas Medicine (NASDAQ:EDIT) on 1/23/2023 |
IONS Ionis Pharmaceuticals | $50.59 +0.2% | 1/23/2023 | Target Raised by | SVB Leerink | - | Market Perform | $32.00 -> $33.00 | Low | View details for SVB Leerink rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 1/23/2023 |
NTLA Intellia Therapeutics | $30.49 -4.0% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $86.00 -> $84.00 | Low | View details for SVB Leerink rating of Intellia Therapeutics (NASDAQ:NTLA) on 1/23/2023 |
RCKT Rocket Pharmaceuticals | $29.97 -3.0% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $50.00 -> $49.00 | Low | View details for SVB Leerink rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 1/23/2023 |
RGNX REGENXBIO | $17.95 -3.2% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $15.00 -> $14.00 | Low | View details for SVB Leerink rating of REGENXBIO (NASDAQ:RGNX) on 1/23/2023 |
RXRX Recursion Pharmaceuticals | $9.86 -7.1% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $9.00 -> $8.00 | Low | View details for SVB Leerink rating of Recursion Pharmaceuticals (NASDAQ:RXRX) on 1/23/2023 |
SRPT Sarepta Therapeutics | $96.43 -1.4% | 1/20/2023 | Reiterated by | SVB Leerink | - | Outperform | $160.00 | Low | View details for SVB Leerink rating of Sarepta Therapeutics (NASDAQ:SRPT) on 1/20/2023 |
ZYME Zymeworks | $10.39 -2.9% | 1/20/2023 | Target Raised by | SVB Leerink | Analyst A. Berens | Market Perform | $8.00 -> $10.00 | Low | View details for SVB Leerink rating of Zymeworks (NYSE:ZYME) on 1/20/2023 |
SGEN Seagen | $228.74
| 1/20/2023 | Target Raised by | SVB Leerink | Analyst Andrew Berens | Outperform | $160.00 -> $162.00 | Low | View details for SVB Leerink rating of Seagen (NASDAQ:SGEN) on 1/20/2023 |
BGNE BeiGene | $180.36 +0.5% | 1/20/2023 | Target Raised by | SVB Leerink | - | Outperform | $236.00 -> $300.00 | Low | View details for SVB Leerink rating of BeiGene (NASDAQ:BGNE) on 1/20/2023 |
JNJ Johnson & Johnson | $156.74 +0.1% | 1/20/2023 | Target Lowered by | SVB Leerink | - | Outperform | $194.00 -> $186.00 | Low | View details for SVB Leerink rating of Johnson & Johnson (NYSE:JNJ) on 1/20/2023 |
MRNA Moderna | $99.45 +0.7% | 1/18/2023 | Target Raised by | SVB Leerink | Analyst M. Foroohar | Market Perform | $102.00 -> $111.00 | Low | View details for SVB Leerink rating of Moderna (NASDAQ:MRNA) on 1/18/2023 |
EOLS Evolus | $10.53 +1.9% | 1/19/2023 | Target Raised by | SVB Leerink | - | Outperform | $18.00 -> $20.00 | Low | View details for SVB Leerink rating of Evolus (NASDAQ:EOLS) on 1/19/2023 |
VRTX Vertex Pharmaceuticals | $406.89 -0.6% | 1/17/2023 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $374.00 | Low | View details for SVB Leerink rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 1/17/2023 |
EXAS Exact Sciences | $73.98 -2.3% | 1/12/2023 | Target Raised by | SVB Leerink | - | Outperform | $70.00 -> $75.00 | Low | View details for SVB Leerink rating of Exact Sciences (NASDAQ:EXAS) on 1/12/2023 |
HOLX Hologic | $71.45 +0.3% | 1/12/2023 | Target Raised by | SVB Leerink | - | Outperform | $85.00 -> $90.00 | Low | View details for SVB Leerink rating of Hologic (NASDAQ:HOLX) on 1/12/2023 |
HALO Halozyme Therapeutics | $36.96 -0.5% | 1/11/2023 | Target Lowered by | SVB Leerink | - | Outperform | $62.00 -> $61.00 | Low | View details for SVB Leerink rating of Halozyme Therapeutics (NASDAQ:HALO) on 1/11/2023 |
MIRM Mirum Pharmaceuticals | $29.52 -1.5% | 1/10/2023 | Target Lowered by | SVB Leerink | - | Outperform | $50.00 -> $39.00 | Low | View details for SVB Leerink rating of Mirum Pharmaceuticals (NASDAQ:MIRM) on 1/10/2023 |
EDIT Editas Medicine | $10.13 -2.1% | 1/10/2023 | Target Lowered by | SVB Leerink | Analyst R. Bienkowski | Market Perform | $7.00 -> $6.00 | Low | View details for SVB Leerink rating of Editas Medicine (NASDAQ:EDIT) on 1/10/2023 |
|
KPTI Karyopharm Therapeutics | $0.87 -6.5% | 1/10/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $6.00 -> $5.00 | Low | View details for SVB Leerink rating of Karyopharm Therapeutics (NASDAQ:KPTI) on 1/10/2023 |
TSVT 2seventy bio | $4.27 -6.8% | 1/10/2023 | Target Lowered by | SVB Leerink | - | Outperform | $41.00 -> $34.00 | Low | View details for SVB Leerink rating of 2seventy bio (NASDAQ:TSVT) on 1/10/2023 |
VRDN Viridian Therapeutics | $21.78 -2.7% | 1/9/2023 | Target Raised by | SVB Leerink | - | Outperform | $40.00 -> $45.00 | Low | View details for SVB Leerink rating of Viridian Therapeutics (NASDAQ:VRDN) on 1/9/2023 |
BLUE bluebird bio | $1.38 -2.1% | 1/6/2023 | Target Raised by | SVB Leerink | - | Market Perform | $8.00 -> $9.00 | Low | View details for SVB Leerink rating of bluebird bio (NASDAQ:BLUE) on 1/6/2023 |
EXAS Exact Sciences | $73.98 -2.3% | 1/6/2023 | Target Raised by | SVB Leerink | - | Outperform | $60.00 -> $70.00 | Low | View details for SVB Leerink rating of Exact Sciences (NASDAQ:EXAS) on 1/6/2023 |
HOLX Hologic | $71.45 +0.3% | 1/6/2023 | Target Raised by | SVB Leerink | - | Outperform | $78.00 -> $85.00 | Low | View details for SVB Leerink rating of Hologic (NASDAQ:HOLX) on 1/6/2023 |
A Agilent Technologies | $139.03 -0.4% | 1/6/2023 | Target Raised by | SVB Leerink | - | Outperform | $160.00 -> $170.00 | Low | View details for SVB Leerink rating of Agilent Technologies (NYSE:A) on 1/6/2023 |
ABCL AbCellera Biologics | $5.71 -3.7% | 1/6/2023 | Target Lowered by | SVB Leerink | - | Outperform | $20.00 -> $18.00 | Low | View details for SVB Leerink rating of AbCellera Biologics (NASDAQ:ABCL) on 1/6/2023 |
MASS 908 Devices | $11.22 -9.6% | 1/6/2023 | Target Lowered by | SVB Leerink | - | Outperform | $25.00 -> $20.00 | Low | View details for SVB Leerink rating of 908 Devices (NASDAQ:MASS) on 1/6/2023 |
RGEN Repligen | $179.80 -3.0% | 1/6/2023 | Target Lowered by | SVB Leerink | - | Outperform | $230.00 -> $200.00 | Low | View details for SVB Leerink rating of Repligen (NASDAQ:RGEN) on 1/6/2023 |
TMO Thermo Fisher Scientific | $530.79 -0.4% | 1/6/2023 | Target Raised by | SVB Leerink | - | Outperform | $555.00 -> $620.00 | Low | View details for SVB Leerink rating of Thermo Fisher Scientific (NYSE:TMO) on 1/6/2023 |
WAT Waters | $329.23 -1.1% | 1/6/2023 | Target Raised by | SVB Leerink | - | Market Perform | $320.00 -> $352.00 | Low | View details for SVB Leerink rating of Waters (NYSE:WAT) on 1/6/2023 |
FATE Fate Therapeutics | $3.74 -5.1% | 1/6/2023 | Target Lowered by | SVB Leerink | - | Outperform | $62.00 -> $10.00 | N/A | View details for SVB Leerink rating of Fate Therapeutics (NASDAQ:FATE) on 1/6/2023 |
IPSC Century Therapeutics | $3.32 +7.1% | 1/6/2023 | Target Lowered by | SVB Leerink | - | Outperform | $20.00 -> $14.00 | Low | View details for SVB Leerink rating of Century Therapeutics (NASDAQ:IPSC) on 1/6/2023 |
GRPH Graphite Bio | $2.62 -1.5% | 1/6/2023 | Downgraded by | SVB Leerink | Analyst M. Foroohar | Outperform -> Market Perform | $11.00 -> $2.00 | Low | View details for SVB Leerink rating of Graphite Bio (NASDAQ:GRPH) on 1/6/2023 |
AMED Amedisys | $95.06 +0.0% | 1/5/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $96.00 -> $85.00 | Low | View details for SVB Leerink rating of Amedisys (NASDAQ:AMED) on 1/5/2023 |
COGT Cogent Biosciences | $5.88 -2.8% | 1/5/2023 | Target Raised by | SVB Leerink | - | Outperform | $18.00 -> $20.00 | Low | View details for SVB Leerink rating of Cogent Biosciences (NASDAQ:COGT) on 1/5/2023 |
PGNY Progyny | $37.18 -1.5% | 1/5/2023 | Reiterated by | SVB Leerink | Analyst S. Davis | Outperform -> Market Perform | $59.00 -> $34.00 | Low | View details for SVB Leerink rating of Progyny (NASDAQ:PGNY) on 1/5/2023 |
PHR Phreesia | $23.15 -1.9% | 1/5/2023 | Target Raised by | SVB Leerink | Analyst S. Davis | Outperform | $34.00 -> $39.00 | Low | View details for SVB Leerink rating of Phreesia (NYSE:PHR) on 1/5/2023 |
DCPH Deciphera Pharmaceuticals | $16.13 -1.8% | 1/4/2023 | Target Raised by | SVB Leerink | - | Outperform | $25.00 -> $28.00 | Low | View details for SVB Leerink rating of Deciphera Pharmaceuticals (NASDAQ:DCPH) on 1/4/2023 |
AMTI Applied Molecular Transport | $0.26
| 12/27/2022 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of Applied Molecular Transport (NASDAQ:AMTI) on 12/27/2022 |
AMGN Amgen | $288.02 -0.2% | 12/22/2022 | Target Raised by | SVB Leerink | - | Market Perform | $256.00 -> $282.00 | Low | View details for SVB Leerink rating of Amgen (NASDAQ:AMGN) on 12/22/2022 |
RCKT Rocket Pharmaceuticals | $29.97 -3.0% | 12/22/2022 | Target Lowered by | SVB Leerink | - | Outperform | $54.00 -> $50.00 | Low | View details for SVB Leerink rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 12/22/2022 |
MDGL Madrigal Pharmaceuticals | $231.38 -1.1% | 12/20/2022 | Target Raised by | SVB Leerink | - | Outperform | $145.00 -> $315.00 | Low | View details for SVB Leerink rating of Madrigal Pharmaceuticals (NASDAQ:MDGL) on 12/20/2022 |
NAMS NewAmsterdam Pharma | $11.17 -2.3% | 12/20/2022 | Initiated by | SVB Leerink | Analyst R. Ruiz | Outperform | $19.00 | Low | View details for SVB Leerink rating of NewAmsterdam Pharma (NASDAQ:NAMS) on 12/20/2022 |
PCVX Vaxcyte | $62.80 -0.8% | 12/16/2022 | Reiterated by | SVB Leerink | Analyst D. Risinger | Outperform | $60.00 | Low | View details for SVB Leerink rating of Vaxcyte (NASDAQ:PCVX) on 12/16/2022 |
HCA HCA Healthcare | $270.68 +0.1% | 12/16/2022 | Target Raised by | SVB Leerink | - | Outperform | $238.00 -> $286.00 | Low | View details for SVB Leerink rating of HCA Healthcare (NYSE:HCA) on 12/16/2022 |
LLY Eli Lilly and Company | $582.92 +0.4% | 12/16/2022 | Target Raised by | SVB Leerink | - | Outperform | $384.00 -> $410.00 | Low | View details for SVB Leerink rating of Eli Lilly and Company (NYSE:LLY) on 12/16/2022 |
ROIV Roivant Sciences | $11.23 -1.2% | 12/19/2022 | Target Raised by | SVB Leerink | - | Outperform | $8.00 -> $10.00 | Low | View details for SVB Leerink rating of Roivant Sciences (NASDAQ:ROIV) on 12/19/2022 |
KYMR Kymera Therapeutics | $25.46 -5.1% | 12/15/2022 | Target Raised by | SVB Leerink | Analyst M. Kratky | Market Perform | $26.00 -> $31.00 | Low | View details for SVB Leerink rating of Kymera Therapeutics (NASDAQ:KYMR) on 12/15/2022 |
WVE Wave Life Sciences | $5.05 -0.2% | 12/14/2022 | Target Raised by | SVB Leerink | Analyst M. Foroohar | Market Perform | $2.00 -> $7.00 | Low | View details for SVB Leerink rating of Wave Life Sciences (NASDAQ:WVE) on 12/14/2022 |
MRTX Mirati Therapeutics | $58.75 -0.3% | 12/14/2022 | Target Lowered by | SVB Leerink | - | Outperform | $85.00 -> $75.00 | Low | View details for SVB Leerink rating of Mirati Therapeutics (NASDAQ:MRTX) on 12/14/2022 |
MIRM Mirum Pharmaceuticals | $29.52 -1.5% | 12/14/2022 | Target Raised by | SVB Leerink | - | Outperform | $49.00 -> $50.00 | Low | View details for SVB Leerink rating of Mirum Pharmaceuticals (NASDAQ:MIRM) on 12/14/2022 |
MRNA Moderna | $99.45 +0.7% | 12/13/2022 | Target Raised by | SVB Leerink | Analyst M. Foroohar | Market Perform | $101.00 -> $102.00 | Low | View details for SVB Leerink rating of Moderna (NASDAQ:MRNA) on 12/13/2022 |
NRIX Nurix Therapeutics | $10.32 -3.6% | 12/13/2022 | Target Lowered by | SVB Leerink | - | Outperform | $37.00 -> $28.00 | Low | View details for SVB Leerink rating of Nurix Therapeutics (NASDAQ:NRIX) on 12/13/2022 |
SPRY ARS Pharmaceuticals | $5.48 -2.7% | 12/13/2022 | Initiated by | SVB Leerink | Analyst Roanna Ruiz | Outperform | $14.00 | Low | View details for SVB Leerink rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 12/13/2022 |
FATE Fate Therapeutics | $3.74 -5.1% | 12/13/2022 | Target Lowered by | SVB Leerink | - | Outperform | $64.00 -> $62.00 | Low | View details for SVB Leerink rating of Fate Therapeutics (NASDAQ:FATE) on 12/13/2022 |
BGNE BeiGene | $180.36 +0.5% | 12/12/2022 | Target Raised by | SVB Leerink | - | Outperform | $210.00 -> $236.00 | Low | View details for SVB Leerink rating of BeiGene (NASDAQ:BGNE) on 12/12/2022 |
AFMD Affimed | $0.63 +16.8% | 12/12/2022 | Target Lowered by | SVB Leerink | - | Outperform | $10.00 -> $6.00 | Low | View details for SVB Leerink rating of Affimed (NASDAQ:AFMD) on 12/12/2022 |
DSGN Design Therapeutics | $2.65 -4.0% | 12/9/2022 | Target Lowered by | SVB Leerink | - | Outperform | $30.00 -> $22.00 | Low | View details for SVB Leerink rating of Design Therapeutics (NASDAQ:DSGN) on 12/9/2022 |
PHR Phreesia | $23.15 -1.9% | 12/9/2022 | Upgraded by | SVB Leerink | Analyst Stephanie Davis | Market Perform -> Outperform | $31.00 -> $34.00 | Low | View details for SVB Leerink rating of Phreesia (NYSE:PHR) on 12/9/2022 |
MRTX Mirati Therapeutics | $58.75 -0.3% | 12/8/2022 | Target Lowered by | SVB Leerink | - | Outperform | $102.00 -> $85.00 | Low | View details for SVB Leerink rating of Mirati Therapeutics (NASDAQ:MRTX) on 12/8/2022 |
REPL Replimune Group | $8.43 -1.9% | 12/7/2022 | Target Raised by | SVB Leerink | - | Outperform | $30.00 -> $34.00 | Low | View details for SVB Leerink rating of Replimune Group (NASDAQ:REPL) on 12/7/2022 |
GOSS Gossamer Bio | $0.91 +3.4% | 12/7/2022 | Target Lowered by | SVB Leerink | - | Outperform | $15.00 -> $10.00 | Low | View details for SVB Leerink rating of Gossamer Bio (NASDAQ:GOSS) on 12/7/2022 |
RCKT Rocket Pharmaceuticals | $29.97 -3.0% | 12/6/2022 | Target Lowered by | SVB Leerink | - | Outperform | $56.00 -> $54.00 | Low | View details for SVB Leerink rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 12/6/2022 |
VEEV Veeva Systems | $192.52 -0.8% | 12/2/2022 | Target Lowered by | SVB Leerink | - | Outperform | $242.00 -> $233.00 | Low | View details for SVB Leerink rating of Veeva Systems (NYSE:VEEV) on 12/2/2022 |
NTLA Intellia Therapeutics | $30.49 -4.0% | 12/2/2022 | Target Lowered by | SVB Leerink | - | Outperform | $90.00 -> $86.00 | Low | View details for SVB Leerink rating of Intellia Therapeutics (NASDAQ:NTLA) on 12/2/2022 |
LNTH Lantheus | $62.00 -0.4% | 11/30/2022 | Initiated by | SVB Leerink | - | Outperform | | Low | View details for SVB Leerink rating of Lantheus (NASDAQ:LNTH) on 11/30/2022 |
PNT POINT Biopharma Global | $12.50
| 11/30/2022 | Initiated by | SVB Leerink | Analyst Faisal Khurshid | Outperform | $14.00 | Low | View details for SVB Leerink rating of POINT Biopharma Global (NASDAQ:PNT) on 11/30/2022 |
FUSN Fusion Pharmaceuticals | $9.61 -0.4% | 11/30/2022 | Initiated by | SVB Leerink | Analyst Faisal Khurshid | Outperform | $6.00 | Low | View details for SVB Leerink rating of Fusion Pharmaceuticals (NASDAQ:FUSN) on 11/30/2022 |
|
OABI OmniAb | $6.17 +0.8% | 11/29/2022 | Initiated by | SVB Leerink | Analyst Puneet Souda | Outperform | $6.00 | Low | View details for SVB Leerink rating of OmniAb (NASDAQ:OABI) on 11/29/2022 |
AXSM Axsome Therapeutics | $79.59 0.0% | 11/29/2022 | Target Raised by | SVB Leerink | - | Outperform | $65.00 -> $85.00 | Low | View details for SVB Leerink rating of Axsome Therapeutics (NASDAQ:AXSM) on 11/29/2022 |
ARWR Arrowhead Pharmaceuticals | $30.60 -1.3% | 11/29/2022 | Target Lowered by | SVB Leerink | - | Market Perform | $33.00 -> $31.00 | Low | View details for SVB Leerink rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 11/29/2022 |
FATE Fate Therapeutics | $3.74 -5.1% | 11/24/2022 | Target Set by | SVB Leerink | - | | $64.00 | Low | View details for SVB Leerink rating of Fate Therapeutics (NASDAQ:FATE) on 11/24/2022 |
ACLX Arcellx | $55.50 -2.4% | 11/24/2022 | Target Lowered by | SVB Leerink | - | | $35.00 | Low | View details for SVB Leerink rating of Arcellx (NASDAQ:ACLX) on 11/24/2022 |
TRVI Trevi Therapeutics | $1.34 -3.6% | 11/22/2022 | Initiated by | SVB Leerink | Analyst T. Smith | Outperform | $6.00 | Low | View details for SVB Leerink rating of Trevi Therapeutics (NASDAQ:TRVI) on 11/22/2022 |
ARVN Arvinas | $41.16 -2.0% | 11/22/2022 | Target Lowered by | SVB Leerink | - | Outperform | $89.00 -> $74.00 | Low | View details for SVB Leerink rating of Arvinas (NASDAQ:ARVN) on 11/22/2022 |
SGRY Surgery Partners | $31.99 -0.6% | 11/22/2022 | Target Lowered by | SVB Leerink | Analyst W. Mayo | Outperform | $55.00 -> $40.00 | Low | View details for SVB Leerink rating of Surgery Partners (NASDAQ:SGRY) on 11/22/2022 |
A Agilent Technologies | $139.03 -0.4% | 11/22/2022 | Target Raised by | SVB Leerink | - | Outperform | $145.00 -> $160.00 | Low | View details for SVB Leerink rating of Agilent Technologies (NYSE:A) on 11/22/2022 |
ALPN Alpine Immune Sciences | $19.06 -2.6% | 11/21/2022 | Initiated by | SVB Leerink | Analyst T. Smith | Outperform | $15.00 | Low | View details for SVB Leerink rating of Alpine Immune Sciences (NASDAQ:ALPN) on 11/21/2022 |
TWST Twist Bioscience | $36.86 -3.5% | 11/21/2022 | Target Lowered by | SVB Leerink | - | Market Perform | $45.00 -> $30.00 | Low | View details for SVB Leerink rating of Twist Bioscience (NASDAQ:TWST) on 11/21/2022 |
EDIT Editas Medicine | $10.13 -2.1% | 11/17/2022 | Target Lowered by | SVB Leerink | Analyst R. Bienkowski | Market Perform | $14.00 -> $7.00 | Low | View details for SVB Leerink rating of Editas Medicine (NASDAQ:EDIT) on 11/17/2022 |
TBPH Theravance Biopharma | $11.24 -0.6% | 11/17/2022 | Target Raised by | SVB Leerink | - | Outperform | $12.00 -> $14.00 | Low | View details for SVB Leerink rating of Theravance Biopharma (NASDAQ:TBPH) on 11/17/2022 |
COGT Cogent Biosciences | $5.88 -2.8% | 11/17/2022 | Target Lowered by | SVB Leerink | - | Outperform | $20.00 -> $18.00 | Low | View details for SVB Leerink rating of Cogent Biosciences (NASDAQ:COGT) on 11/17/2022 |
OLK Olink Holding AB (publ) | $25.15 -0.2% | 11/15/2022 | Target Raised by | SVB Leerink | - | Outperform | $25.00 -> $27.00 | Low | View details for SVB Leerink rating of Olink Holding AB (publ) (NASDAQ:OLK) on 11/15/2022 |
LNTH Lantheus | $62.00 -0.4% | 11/15/2022 | Target Raised by | SVB Leerink | - | Outperform | $110.00 -> $120.00 | Low | View details for SVB Leerink rating of Lantheus (NASDAQ:LNTH) on 11/15/2022 |
IPHA Innate Pharma | $2.80 +1.8% | 11/15/2022 | Target Lowered by | SVB Leerink | - | Outperform | $10.00 -> $9.00 | Low | View details for SVB Leerink rating of Innate Pharma (NASDAQ:IPHA) on 11/15/2022 |
ROIV Roivant Sciences | $11.23 -1.2% | 11/15/2022 | Target Raised by | SVB Leerink | - | Outperform | $7.00 -> $8.00 | Low | View details for SVB Leerink rating of Roivant Sciences (NASDAQ:ROIV) on 11/15/2022 |
MASS 908 Devices | $11.22 -9.6% | 11/15/2022 | Target Lowered by | SVB Leerink | - | Outperform | $30.00 -> $25.00 | Low | View details for SVB Leerink rating of 908 Devices (NASDAQ:MASS) on 11/15/2022 |
HARP Harpoon Therapeutics | $11.37 -0.6% | 11/15/2022 | Target Lowered by | SVB Leerink | - | Outperform | $100.00 -> $40.00 | Low | View details for SVB Leerink rating of Harpoon Therapeutics (NASDAQ:HARP) on 11/15/2022 |
ASND Ascendis Pharma A/S | $125.95 -1.1% | 11/14/2022 | Target Lowered by | SVB Leerink | - | Outperform | $168.00 -> $148.00 | Low | View details for SVB Leerink rating of Ascendis Pharma A/S (NASDAQ:ASND) on 11/14/2022 |
AIRS AirSculpt Technologies | $7.49 -0.3% | 11/14/2022 | Target Lowered by | SVB Leerink | - | Outperform | $27.00 -> $8.00 | Low | View details for SVB Leerink rating of AirSculpt Technologies (NASDAQ:AIRS) on 11/14/2022 |
HALO Halozyme Therapeutics | $36.96 -0.5% | 11/14/2022 | Target Raised by | SVB Leerink | - | Outperform | $52.00 -> $62.00 | Low | View details for SVB Leerink rating of Halozyme Therapeutics (NASDAQ:HALO) on 11/14/2022 |
IFRX InflaRx | $1.63 -1.8% | 11/9/2022 | Reiterated by | SVB Leerink | Analyst J. Schwartz | Outperform | | Low | View details for SVB Leerink rating of InflaRx (NASDAQ:IFRX) on 11/9/2022 |
PRVA Privia Health Group | $23.03 -3.8% | 11/11/2022 | Target Lowered by | SVB Leerink | - | Outperform | $46.00 -> $39.00 | Low | View details for SVB Leerink rating of Privia Health Group (NASDAQ:PRVA) on 11/11/2022 |
PEPG PepGen | $6.80 -3.5% | 11/10/2022 | Target Lowered by | SVB Leerink | Analyst J. Schwartz | Outperform | $40.00 -> $33.00 | Low | View details for SVB Leerink rating of PepGen (NASDAQ:PEPG) on 11/10/2022 |
FDMT 4D Molecular Therapeutics | $20.26 -3.6% | 11/10/2022 | Target Raised by | SVB Leerink | Analyst M. Foroohar | Market Perform | $10.00 -> $11.00 | Low | View details for SVB Leerink rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 11/10/2022 |
GMAB Genmab A/S | $31.84 -0.3% | 11/10/2022 | Target Raised by | SVB Leerink | - | Market Perform | $33.00 | Low | View details for SVB Leerink rating of Genmab A/S (NASDAQ:GMAB) on 11/10/2022 |
ARWR Arrowhead Pharmaceuticals | $30.60 -1.3% | 11/10/2022 | Target Raised by | SVB Leerink | - | Market Perform | $32.00 -> $33.00 | Low | View details for SVB Leerink rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 11/10/2022 |
MREO Mereo BioPharma Group | $2.31 -0.9% | 11/10/2022 | Target Lowered by | SVB Leerink | - | Outperform | $8.00 -> $4.00 | Low | View details for SVB Leerink rating of Mereo BioPharma Group (NASDAQ:MREO) on 11/10/2022 |
IONS Ionis Pharmaceuticals | $50.59 +0.2% | 11/10/2022 | Target Lowered by | SVB Leerink | - | Market Perform | $30.00 -> $26.00 | Low | View details for SVB Leerink rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 11/10/2022 |
BGNE BeiGene | $180.36 +0.5% | 11/10/2022 | Target Raised by | SVB Leerink | - | Outperform | $200.00 -> $210.00 | Low | View details for SVB Leerink rating of BeiGene (NASDAQ:BGNE) on 11/10/2022 |
SCPH scPharmaceuticals | $6.27 -1.9% | 11/10/2022 | Target Raised by | SVB Leerink | Analyst R. Ruiz | Outperform | $11.00 -> $12.00 | Low | View details for SVB Leerink rating of scPharmaceuticals (NASDAQ:SCPH) on 11/10/2022 |
AHCO AdaptHealth | $7.29 -0.4% | 11/10/2022 | Target Raised by | SVB Leerink | Analyst Whit Mayo | Outperform | $29.00 -> $30.00 | Low | View details for SVB Leerink rating of AdaptHealth (NASDAQ:AHCO) on 11/10/2022 |
SGRY Surgery Partners | $31.99 -0.6% | 11/10/2022 | Target Lowered by | SVB Leerink | Analyst W. Mayo | Outperform | $57.00 -> $55.00 | Low | View details for SVB Leerink rating of Surgery Partners (NASDAQ:SGRY) on 11/10/2022 |
ZNTL Zentalis Pharmaceuticals | $15.15 -2.8% | 11/10/2022 | Target Lowered by | SVB Leerink | - | Outperform | $42.00 -> $27.00 | Low | View details for SVB Leerink rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on 11/10/2022 |
ACRS Aclaris Therapeutics | $1.05 -1.9% | 11/8/2022 | Reiterated by | SVB Leerink | Analyst T. Smith | Outperform | | Low | View details for SVB Leerink rating of Aclaris Therapeutics (NASDAQ:ACRS) on 11/8/2022 |
NEO NeoGenomics | $16.18 -3.6% | 11/9/2022 | Target Raised by | SVB Leerink | - | Outperform | $12.00 -> $15.00 | Low | View details for SVB Leerink rating of NeoGenomics (NASDAQ:NEO) on 11/9/2022 |
RCM R1 RCM | $10.57 -1.5% | 11/9/2022 | Target Lowered by | SVB Leerink | - | Outperform | $35.00 -> $16.00 | Low | View details for SVB Leerink rating of R1 RCM (NASDAQ:RCM) on 11/9/2022 |
TALK Talkspace | $2.54 -0.8% | 11/9/2022 | Target Lowered by | SVB Leerink | - | Market Perform | $2.00 -> $1.00 | Low | View details for SVB Leerink rating of Talkspace (NASDAQ:TALK) on 11/9/2022 |
ABCL AbCellera Biologics | $5.71 -3.7% | 11/9/2022 | Target Raised by | SVB Leerink | - | Outperform | $13.00 -> $20.00 | Low | View details for SVB Leerink rating of AbCellera Biologics (NASDAQ:ABCL) on 11/9/2022 |
QTRX Quanterix | $27.34 -4.6% | 11/9/2022 | Target Raised by | SVB Leerink | Analyst P. Souda | Market Perform | $12.00 -> $15.00 | Low | View details for SVB Leerink rating of Quanterix (NASDAQ:QTRX) on 11/9/2022 |
HCAT Health Catalyst | $9.26 -3.2% | 11/9/2022 | Target Lowered by | SVB Leerink | - | Outperform | $20.00 -> $17.00 | Low | View details for SVB Leerink rating of Health Catalyst (NASDAQ:HCAT) on 11/9/2022 |
MRTX Mirati Therapeutics | $58.75 -0.3% | 11/9/2022 | Target Lowered by | SVB Leerink | - | Outperform | $111.00 -> $102.00 | Low | View details for SVB Leerink rating of Mirati Therapeutics (NASDAQ:MRTX) on 11/9/2022 |
MNKD MannKind | $3.64 -1.6% | 11/9/2022 | Target Raised by | SVB Leerink | - | Outperform | $5.00 -> $6.00 | Low | View details for SVB Leerink rating of MannKind (NASDAQ:MNKD) on 11/9/2022 |
NVTA Invitae | $0.63 -6.0% | 11/9/2022 | Target Raised by | SVB Leerink | Analyst P. Souda | Market Perform | $2.50 -> $3.00 | Low | View details for SVB Leerink rating of Invitae (NYSE:NVTA) on 11/9/2022 |
HIMS Hims & Hers Health | $8.90 -1.4% | 11/8/2022 | Upgraded by | SVB Leerink | Analyst J. Zhang | Market Perform -> Outperform | $5.00 | Low | View details for SVB Leerink rating of Hims & Hers Health (NYSE:HIMS) on 11/8/2022 |
TSVT 2seventy bio | $4.27 -6.8% | 11/8/2022 | Target Lowered by | SVB Leerink | - | Outperform | $42.00 -> $41.00 | Low | View details for SVB Leerink rating of 2seventy bio (NASDAQ:TSVT) on 11/8/2022 |
CLOV Clover Health Investments | $0.95 -2.1% | 11/8/2022 | Target Lowered by | SVB Leerink | - | Market Perform | $3.00 -> $1.50 | Low | View details for SVB Leerink rating of Clover Health Investments (NASDAQ:CLOV) on 11/8/2022 |
CI The Cigna Group | $299.45 +0.0% | 11/8/2022 | Target Raised by | SVB Leerink | - | Market Perform | $305.00 -> $335.00 | Low | View details for SVB Leerink rating of The Cigna Group (NYSE:CI) on 11/8/2022 |
AMTI Applied Molecular Transport | $0.26
| 11/8/2022 | Target Lowered by | SVB Leerink | - | Outperform | $21.00 -> $15.00 | Low | View details for SVB Leerink rating of Applied Molecular Transport (NASDAQ:AMTI) on 11/8/2022 |
BEAM Beam Therapeutics | $27.22 -7.5% | 11/7/2022 | Target Lowered by | SVB Leerink | - | Outperform | $82.00 -> $81.00 | Low | View details for SVB Leerink rating of Beam Therapeutics (NASDAQ:BEAM) on 11/7/2022 |
ELEV Elevation Oncology | $0.54 -1.8% | 11/7/2022 | Downgraded by | SVB Leerink | Analyst A. Berens | Outperform -> Market Perform | $11.00 -> $2.00 | Low | View details for SVB Leerink rating of Elevation Oncology (NASDAQ:ELEV) on 11/7/2022 |
ALNY Alnylam Pharmaceuticals | $191.41 -2.2% | 11/7/2022 | Target Raised by | SVB Leerink | - | Market Perform | $142.00 -> $145.00 | Low | View details for SVB Leerink rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 11/7/2022 |
ALVR AlloVir | $0.68
| 11/7/2022 | Target Raised by | SVB Leerink | - | Outperform | $24.00 -> $25.00 | Low | View details for SVB Leerink rating of AlloVir (NASDAQ:ALVR) on 11/7/2022 |
CRSP CRISPR Therapeutics | $62.60 -2.6% | 11/7/2022 | Target Raised by | SVB Leerink | - | Outperform | $75.00 -> $76.00 | Low | View details for SVB Leerink rating of CRISPR Therapeutics (NASDAQ:CRSP) on 11/7/2022 |
IMVT Immunovant | $42.13 -0.5% | 11/4/2022 | Target Raised by | SVB Leerink | - | Outperform | $12.00 -> $14.00 | Low | View details for SVB Leerink rating of Immunovant (NASDAQ:IMVT) on 11/4/2022 |
MRUS Merus | $27.50 -2.2% | 11/4/2022 | Target Lowered by | SVB Leerink | - | Outperform | $39.00 -> $35.00 | Low | View details for SVB Leerink rating of Merus (NASDAQ:MRUS) on 11/4/2022 |
RGNX REGENXBIO | $17.95 -3.2% | 11/4/2022 | Target Raised by | SVB Leerink | - | Market Perform | $13.00 -> $14.00 | Low | View details for SVB Leerink rating of REGENXBIO (NASDAQ:RGNX) on 11/4/2022 |
KPTI Karyopharm Therapeutics | $0.87 -6.5% | 11/4/2022 | Target Raised by | SVB Leerink | - | Market Perform | $5.00 -> $6.00 | Low | View details for SVB Leerink rating of Karyopharm Therapeutics (NASDAQ:KPTI) on 11/4/2022 |